ImpediMed Limited (ASX: IPD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
ImpediMed Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
ImpediMed Limited (ASX: IPD)
Latest News
⏸️ Investing
Impedimed Limited share price climbs higher on FDA clearance
⏸️ Investing
Why these 4 ASX shares have climbed higher today
⏸️ Investing
The ImpediMed Limited share price has jumped: Here's why
⏸️ Investing
Why these 4 ASX shares are ending the week deep in the red
⏸️ Investing
Why these 4 ASX shares have rocketed higher today
⏸️ Investing
Why these 4 ASX shares have started the week deep in the red
⏸️ Investing
Why these 4 ASX shares surged higher today
⏸️ Investing
Why these 4 ASX shares have bolted higher today
⏸️ Investing
5 explosive growth shares I will be watching in 2017
⏸️ Investing
4 small-cap shares I think could be set to soar in 2017
⏸️ Investing
3 game-changing companies to buy today
⏸️ Investing
Broker tips 9 small cap stars to buy in October
Frequently Asked Questions
-
No, Impedimed does not pay shareholder dividends at this time.
-
Impedimed Limited listed on the ASX on 24 October 2007.
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About ImpediMed Limited
Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.
The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.
As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Sep 2024 | Andrew Grant | Buy | 600,000 | $28,530 |
On-market trade.
|
| 30 Aug 2024 | Andrew Grant | Buy | 1,000,000 | $49,600 |
On-market trade.
|
| 30 Aug 2024 | Christine Emmanuel-Donnelly | Buy | 200,000 | $10,000 |
On-market trade.
|
| 14 May 2024 | Christine Emmanuel-Donnelly | Buy | 100,000 | $8,000 |
On-market trade.
|
| 06 May 2024 | Andrew Grant | Buy | 100,000 | $8,050 |
On-market trade.
|
| 29 Feb 2024 | Andrew Grant | Buy | 100,000 | $87,000 |
On-market trade.
|
| 28 Feb 2024 | Andrew Grant | Buy | 130,000 | $10,920 |
On-market trade.
|
| 28 Feb 2024 | Christine Emmanuel-Donnelly | Buy | 121,952 | $10,169 |
On-market trade.
|
| 13 Dec 2023 | Christine Emmanuel-Donnelly | Buy | 67,857 | $9,499 |
On-market trade.
|
| 04 Dec 2023 | Andrew Grant | Buy | 70,000 | $9,625 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | Sep 2023 |
Ms Emmanuel-Donnelly brings 30 years in IP expertise through commercialisation and strategic in-house intellectual property roles. She has more than 4 years in Board and healthcare governance experience. She is a member of the Risk Committee.
|
| Steven Chen | Chief Medical Officer |
-
|
|
| Ashley Munoz | Director Human Resources |
-
|
|
| Andrew Grant | Executive Director VP Product Development & Customer Solutions |
-
|
|
| Julie Kuhlken | Senior Director Downstream Marketing |
-
|
|
| Dennis Schlaht | SVP R&D and Technology |
-
|
|
| Tim Benkovic | SVP Sales & Customer Success |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 177,180,440 | 8.76% |
| HSBC Custody Nominees (Australia) Limited | 164,419,200 | 8.13% |
| Jp Morgan Nominees Australia Pty Limited | 148,941,253 | 7.36% |
| National Nominees Limited | 115,304,879 | 5.70% |
| HSBC Custody Nominees (Australia) Limited i | 55,570,348 | 2.75% |
| BNP Paribas Noms Pty Ltd | 34,426,377 | 1.70% |
| Sunlora Pty Ltd | 32,125,000 | 1.59% |
| Moore Family Nominee Pty Ltd | 30,000,000 | 1.48% |
| Mr Hamish Alexander Jones | 23,538,705 | 1.16% |
| Mba Investments Pty Ltd | 22,490,990 | 1.11% |
| Mr Gregory Wayne Brown | 20,300,000 | 1.00% |
| Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 19,000,000 | 0.94% |
| Bnp Paribas Nominees Pty Ltd i | 18,925,694 | 0.94% |
| Pakasoluto Pty Limited | 16,011,422 | 0.79% |
| Mr Hsien Michael Soo | 15,662,797 | 0.77% |
| First Samuel Ltd Acn 086243567 | 15,281,508 | 0.76% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 14,251,964 | 0.70% |
| Bsd Pty Ltd | 13,495,000 | 0.67% |
| Hme Soo Holdings Pty Ltd | 12,320,921 | 0.61% |
| Bnp Paribas Nominees Pty Ltd ii | 11,693,112 | 0.58% |
